èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã AC Immune SA ã¯ãã¿ã³ãã¯è³ªã®ãã¹ãã©ãŒã«ãã£ã³ã°ã«é¢é£ããç¥çµå€æ§çŸæ£ã®äºé²ãšæ²»çã®ããã®å»è¬åãšèšºæçšè£œåã®çºèŠãèšèšãéçºãè¡ã£ãŠããŸããå瀟㮠SupraAntigen ããã³ Morphomer ãã©ãããã©ãŒã ã¯ãããŸããŸãªç¥çµå€æ§çŸæ£ã«å
±éãããã¹ãã©ãŒã«ãã¿ã³ãã¯è³ªãšéžæçã«çžäºäœçšããã¯ã¯ãã³ãæäœãå°ååãçæããããã«èšèšãããŠããŸããå瀟ã¯ãã¢ã«ããã€ããŒç
(AD) ã®æ²»çã®ããã®ç¬¬ II çžèšåºäºé²è©Šéšäžã§ãããããåç«äœé
座ç¹ç°çã¢ãã¯ããŒãã«æäœ Crenezumab ãéçºããŠããŸãããŸããAD ã®ç¬¬ II çžèšåºè©Šéšäžã§ãããããŠã³çå矀ã®ç¬¬ Ib çžèšåºè©Šéšãå®äºããæ Abeta ã¯ã¯ãã³åè£ ACI-24ã第 Ib çžèšåºè©Šéšãå®äºããæ Tau ã¯ã¯ãã³åè£ ACI-35ãããã³ç¬¬ II çžèšåºè©Šéšäžã® Tau éœé»åæŸåºæå±€æ®åœ± (PET) ç»åãã¬ãŒãµãŒãéçºããŠããŸããããã«ãå瀟ã¯ADããã³NeuroOrphanã®é©å¿çã«å¯Ÿããäœååã¿ãŠåéé»å®³å€ã®ç ç©¶éçºãè¡ã£ãŠããŸããããã«ãTDP-43ãα-ã·ãã¯ã¬ã€ã³ãNLRP3ãã¿ãŒã²ãããšãã蚺æè¬ãå«ããããŸããŸãªç¥çµå€æ§çŸæ£ãã¿ãŒã²ãããšããçºèŠæ®µéããã³åèšåºæ®µéã®ååãä¿æããŠããŸããå瀟ã¯ãGenentech, Inc.ãBiogen International GmbHãJanssen Pharmaceuticals, Inc.ãLife Molecular Imaging SAãEli Lilly and CompanyãWuXi Biologicsãšã©ã€ã»ã³ã¹å¥çŽããã³ææºãçµãã§ããŸããAC Immune SAã¯2003幎ã«èšç«ãããã¹ã€ã¹ã®ããŒã¶ã³ãã«æ¬ç€Ÿã眮ããŠããŸãã